Taipei Taiwan – November 24th, 2021 – iXensor Co., Ltd. (6734.TWO)
In response to solving common pain points of rapid test, iXensor deployed the patented digital diagnostic PixoTech® technology, integrating the algorithm of image analysis, biochemical tests, and health data management, to launch the digital PixoTest® COVID-19 Antigen Test in mid-2021. By utilizing the PixoTest® POCT Analyzer, PixoTest® standardizes test reading, reduces human errors of inaccurate interpretation, and shortens the waiting time for identifying COVID-19 infected people from several hours to only a few minutes.
Established by Taiwan’s Ministry of Economic Affairs in 1993, the Taiwan Excellence Gold Award recognizes innovation and excellence across various industries. It is regarded as the highest honor in Taiwan for industrial design, research and development, quality management, and marketing. iXensor’s PixoTest® COVID-19 Antigen Test was selected to receive the Gold Award out 1179 applications from 210 companies.
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world’s first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women’s health, diabetes, and cardiovascular diseases.